Spring Bank Pharmaceuticals, Inc. (SBPH:NASDAQ) Investor Relations Material

Overview

Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company that specializes in discovering and developing therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. Its lead product candidate, inarigivir soproxil, is aimed at treating chronic hepatitis B virus. The company also has other SMNH product candidates in its pipeline, including an immunotherapeutic agent to potentially treat certain cancers. Spring Bank Pharmaceuticals has a strategic partnership with Gilead Sciences to conduct a Phase II trial on the combination of inarigivir and tenofovir alafenamide for HBV patients. The company was founded in 2002 and is headquartered in Massachusetts.

Annual Reports

Frequently Asked Questions

What is Spring Bank Pharmaceuticals, Inc.'s ticker?

Spring Bank Pharmaceuticals, Inc.'s ticker is SBPH

What exchange is Spring Bank Pharmaceuticals, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Spring Bank Pharmaceuticals, Inc.'s headquarters?

They are based in Hopkinton, Massachusetts

How many employees does Spring Bank Pharmaceuticals, Inc. have?

There are 11-50 employees working at Spring Bank Pharmaceuticals, Inc.

What is Spring Bank Pharmaceuticals, Inc.'s website?

It is https://springbankpharm.com/

What type of sector is Spring Bank Pharmaceuticals, Inc.?

Spring Bank Pharmaceuticals, Inc. is in the Healthcare sector

What type of industry is Spring Bank Pharmaceuticals, Inc.?

Spring Bank Pharmaceuticals, Inc. is in the Biotechnology industry

Who are Spring Bank Pharmaceuticals, Inc.'s peers and competitors?

The following five companies are Spring Bank Pharmaceuticals, Inc.'s industry peers:

- Insys Therapeutics Inc

- Galera Therapeutics, Inc.

- Leap Therapeutics, Inc.

- Enochian Biosciences, Inc.

- TFF Pharmaceuticals